Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status

Published:2019 Issue:10 Volume:10 Page:2139-2144
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Katsura Hideyuki,Suga Yukio,Araya Tomoyuki,Kita Toshiyuki,Yoneda Taro,Tanaka Nobuyoshi,Kawabata Ayumi,Ishita Sotoki,Mase Hiroki

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma;JTO Clinical and Research Reports;2024-01

2. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab;In Vivo;2023

3. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review;Thorax;2022-06-10

4. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review;Lung Cancer;2022-04

5. The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study;Japanese Journal of Clinical Oncology;2022-03-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP